Research Article: Serum Lipid Profiles, Blood Glucose, and High-Sensitivity C-Reactive Protein Levels Among People Living with HIV Taking Dolutegravir and Ritonavir-Boosted Atazanavir-Based Antiretroviral Therapy at Jimma University Medical Center, Southwest Ethiopia,
Abstract:
Since the introduction of antiretroviral therapy (ART), the mortality and morbidity of people living with HIV have been reduced. Even if ART improves and prolongs life, it presents additional burden for people living with HIV from which atherosclerotic cardiovascular disease (ASCVD) accounts for % of all fatalities. The prevalence of cardiovascular disease (CVD) has increased over the past years, with sub-Saharan Africa presenting the greatest effects. An elevated risk of ASCVD was observed in .% of people living with HIV in Ethiopia taking highly active antiretroviral therapy (HAART).
Introduction:
Since the introduction of antiretroviral therapy (ART), the mortality and morbidity of people living with HIV have been reduced. Even if ART improves and prolongs life, it presents additional burden for people living with HIV from which atherosclerotic cardiovascular disease (ASCVD) accounts for % of all fatalities. The prevalence of cardiovascular disease (CVD) has increased over the past years, with sub-Saharan Africa presenting the greatest effects. An elevated risk of ASCVD was observed in .% of people living…
Read more